Bolt Biotherapeutics (BOLT) News Today → Will this $2 AI stock double overnight? (From Behind the Markets) (Ad) Free BOLT Stock Alerts Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBolt Biotherapeutics’ Promising Trajectory in Immuno-Oncology: A Strong Buy Recommendationmarkets.businessinsider.com - March 25 at 2:56 AMVivo Opportunity Fund Holdings, L.P.'s Net Worthbenzinga.com - February 9 at 8:16 AMH.C. Wainwright Reaffirms Their Hold Rating on 60 Degrees Pharmaceuticals, Inc. (SXTP)markets.businessinsider.com - December 27 at 12:18 AMIs Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Invest In Growth?finance.yahoo.com - November 20 at 3:33 PMBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - November 10 at 6:45 PMBolt Biotherapeutics to Present at Stifel 2023 Healthcare Conferencefinance.yahoo.com - November 7 at 10:06 AMBolt Biotherapeutics: Buy Rating Justified by Promising Clinical Results and Strong Financial Outlookmarkets.businessinsider.com - October 24 at 7:41 PMBolt Biotherapeutics: First Patient Dosed In Clinical Trial Of BDC-3042markets.businessinsider.com - October 19 at 5:32 AMBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer's 2023 Annual Meetingbenzinga.com - October 18 at 9:33 AMBolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meetingfinance.yahoo.com - October 18 at 9:33 AMBolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023finance.yahoo.com - October 16 at 10:13 AMBolt Biotherapeutics' BDC-1001 Gets FDA Orphan Drug Designation To Treat Gastric Cancersmarkets.businessinsider.com - September 28 at 9:42 AMBolt Biotherapeutics Announces Issuance of U.S. Patent Covering Dectin-2-Targeting Agonist Antibodies, Including BDC-3042finance.yahoo.com - September 12 at 2:00 PMBolt Biotherapeutics Second Quarter 2023 Earnings: Misses Expectationsfinance.yahoo.com - August 9 at 7:37 AMBolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - August 8 at 8:24 AMBolt Biotherapeutics Initiates Phase 2 Clinical Studies of BDC-1001 in Patients With HER2-Positive Cancerfinance.yahoo.com - August 3 at 7:43 AMBolt Biotherapeutics to Present at BTIG Virtual Biotechnology Conference 2023finance.yahoo.com - July 31 at 9:11 PMAfter COVID, a Continued Push for Diversity in Clinical Trialsmsn.com - July 19 at 8:03 PMH.C. Wainwright Sticks to Their Buy Rating for Bolt Biotherapeutics (BOLT)markets.businessinsider.com - June 5 at 7:48 AMBioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseasesfinance.yahoo.com - May 30 at 10:46 AMBolt Biotherapeutics Highlights Comprehensive Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at 2023 ASCO Annual Meetingfinance.yahoo.com - May 25 at 6:09 PMBenzinga's Top Ratings Upgrades, Downgrades For May 12, 2023msn.com - May 12 at 12:52 PMBolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 11 at 4:23 PMLooking Into Bolt Biotherapeutics's Return On Capital Employedmsn.com - March 30 at 1:29 PMBolt Biotherapeutics to Present at Cowen 43rd Annual Healthcare Conferencefinance.yahoo.com - February 28 at 10:04 AMBolt Biotherapeutics to Present at February Investor Conferencesfinance.yahoo.com - February 1 at 8:15 AMBolt Biotherapeutics Appoints Laura Berner to Board of Directorsfinance.yahoo.com - December 14 at 5:57 PMBolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatefinanznachrichten.de - November 13 at 4:20 PMBolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - November 10 at 5:34 PMBolt Biotherapeutics to Present Preclinical Data on BDC-3042, Dectin-2 Targeting Agonistic Antibody, at the SITC Annual Meetingfinance.yahoo.com - November 7 at 10:31 AMBiohaven Ltd. (BHVN) Expected to Beat Earnings Estimates: Should You Buy?finance.yahoo.com - November 1 at 1:27 PMBolt Biotherapeutics: A Promised Follow Upseekingalpha.com - August 26 at 4:59 PMJ&J (JNJ) Gets EU Nod for Multiple Myeloma Drug Tecvaylifinance.yahoo.com - August 25 at 3:57 PMEli Lilly (LLY) Stock Up More Than 15% YTD: What Lies Ahead?finance.yahoo.com - August 25 at 3:57 PMBolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - August 10 at 4:39 PMIs Bolt Biotherapeutics (NASDAQ:BOLT) In A Good Position To Deliver On Growth Plans?finance.yahoo.com - July 22 at 9:46 AMBolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022 | Morningstarmorningstar.com - May 28 at 9:33 PMBolt Biotherapeutics to Present Ex Vivo Data Characterizing the Myeloid Cell Landscape in Solid Tumors at ASCO 2022finance.yahoo.com - May 27 at 10:48 AMBolt Biotherapeutics Reports First Quarter 2022 Financial Results and Provides Business Highlightsfinance.yahoo.com - May 13 at 1:45 AMArtiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Boardfinance.yahoo.com - May 5 at 9:34 AMBolt Biotherapeutics to Present at 21st Annual Needham Healthcare Conferencefinance.yahoo.com - April 7 at 8:54 AMBolt Biotherapeutics's Return On Capital Employed Overviewbenzinga.com - March 31 at 11:44 AMWe Think Bolt Biotherapeutics (NASDAQ:BOLT) Can Afford To Drive Business Growthnasdaq.com - February 12 at 3:45 PMBolt Biotherapeutics, Inc. Common Stock (BOLT)nasdaq.com - January 18 at 6:54 PMBolt Biotherapeutics Inc Shares Close the Day 10.5% Higher - Daily Wrapnasdaq.com - December 31 at 8:11 AM3 Top Penny Stocks for 2022nasdaq.com - December 29 at 6:32 PMBolt Biotherapeutics Appoints Nicole Onetto, M.D., to Board of Directorsfinance.yahoo.com - December 16 at 12:40 PMBolt Biotherapeutics Reveals Early Data From BDC-1001 Immuno-Oncology Candidatemarkets.businessinsider.com - December 6 at 10:03 AMBolt Biotherapeutics to Present Interim Clinical Data on BDC-1001 Phase 1/2 Clinical Trial at ESMO Immuno-Oncology Congress 2021finance.yahoo.com - December 2 at 8:43 AMBolt Biotherapeutics to Present at Stifel 2021 Virtual Healthcare Conferencefinance.yahoo.com - November 8 at 10:16 AM Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Will this $2 AI stock double overnight? (Ad)It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share! Click here to learn more >>> BOLT Media Mentions By Week BOLT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BOLT News Sentiment▼0.000.38▲Average Basic Materials News Sentiment BOLT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BOLT Articles This Week▼00▲BOLT Articles Average Week Get Bolt Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BOLT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CNSX:BOLT) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bolt Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
